Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03054363 |
|
Recruitment Status :
Active, not recruiting
First Posted : February 15, 2017
Last Update Posted : March 23, 2022
|
Sponsor:
University of Colorado, Denver
Collaborators:
Pfizer
Cascadian Therapeutics
Information provided by (Responsible Party):
University of Colorado, Denver
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Active, not recruiting |
|---|---|
| Estimated Primary Completion Date : | March 18, 2023 |
| Estimated Study Completion Date : | March 31, 2024 |